{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:02:32Z","timestamp":1790301752434,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.cger.2009.12.003","type":"journal-article","created":{"date-parts":[[2010,2,21]],"date-time":"2010-02-21T09:39:46Z","timestamp":1266745186000},"page":"125-147","source":"Crossref","is-referenced-by-count":39,"title":["Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke"],"prefix":"10.1016","volume":"26","author":[{"given":"Rawan","family":"Tarawneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2009.12.003_bib1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1471-4159.2005.03638.x","article-title":"Modifications of the iron-neuromelanin system in Parkinson's disease","volume":"96","author":"Fasano","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.cger.2009.12.003_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-510X(99)00192-6","article-title":"Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data","volume":"170","author":"Ihara","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.cger.2009.12.003_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0024-3205(87)90299-2","article-title":"MPTP, MPP+ and mitochondrial function","volume":"40","author":"Nicklas","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.cger.2009.12.003_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/mds.10695","article-title":"Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations","volume":"19","author":"Muftuoglu","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.cger.2009.12.003_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF03036449","article-title":"MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview","volume":"7","author":"Jackson-Lewis","year":"2005","journal-title":"Neurotox Res"},{"issue":"Suppl","key":"10.1016\/j.cger.2009.12.003_bib8","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1002\/ana.410320722","article-title":"A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease","volume":"32","author":"Fahn","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib9","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1002\/ana.410440724","article-title":"DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism","volume":"44","author":"Shoulson","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","article-title":"The effect of deprenyl and levodopa on the progression of Parkinson's disease","volume":"38","author":"Olanow","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib11","first-page":"2002","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","author":"Parkinson Study Group","year":"1937","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2009.12.003_bib13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.cger.2009.12.003_bib15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0278-5846(96)00103-0","article-title":"Reduced intravenous glutathione in the treatment of early Parkinson's disease","volume":"20","author":"Sechi","year":"1996","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.cger.2009.12.003_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0301-0082(98)00055-0","article-title":"Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches","volume":"57","author":"Behl","year":"1999","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.cger.2009.12.003_bib17","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1212\/WNL.54.6.1265","article-title":"Association of vitamin E and C supplement use with cognitive function and dementia in elderly men","volume":"54","author":"Masaki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib18","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1001\/jama.287.24.3223","article-title":"Dietary intake of antioxidants and risk of Alzheimer disease","volume":"287","author":"Engelhart","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2009.12.003_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1745-7254.2006.00267.x","article-title":"Beneficial effects of melatonin in experimental models of Alzheimer disease","volume":"27","author":"Cheng","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.cger.2009.12.003_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jnr.20350","article-title":"Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition","volume":"79","author":"Youdim","year":"2004","journal-title":"J Neurosci Res"},{"issue":"Suppl","key":"10.1016\/j.cger.2009.12.003_bib21","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1002\/ana.410320724","article-title":"Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders","volume":"32","author":"Hall","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa052980","article-title":"NXY-059 for acute ischemic stroke","volume":"354","author":"Lees","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2009.12.003_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.jcbfm.9600516","article-title":"Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke","volume":"28","author":"Feuerstein","year":"2008","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.cger.2009.12.003_bib24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMoa070240","article-title":"NXY-059 for the treatment of acute ischemic stroke","volume":"357","author":"Shuaib","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2009.12.003_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1568007053544156","article-title":"Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers","volume":"4","author":"Green","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/JAD-2008-15314","article-title":"Antioxidants in central nervous system diseases: preclinical promise and translational challenges","volume":"15","author":"Kamat","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","author":"Huntington Study Group","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib28","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","article-title":"Trial of d-alpha-tocopherol in Huntington's disease","volume":"152","author":"Peyser","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cger.2009.12.003_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02740748","article-title":"Glutamate and Parkinson's disease","volume":"12","author":"Blandini","year":"1996","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.cger.2009.12.003_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0026-895X(24)23206-5","article-title":"Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease","volume":"57","author":"Dunah","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cger.2009.12.003_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cger.2009.12.003_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cger.2009.12.003_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0006-8993(01)03147-X","article-title":"MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats","volume":"926","author":"Jonkers","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.cger.2009.12.003_bib34","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.46.6.1551","article-title":"Amantadine treatment is an independent predictor of improved survival in Parkinson's disease","volume":"46","author":"Uitti","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.870130307","article-title":"A trial of dextromethorphan in parkinsonian patients with motor response complications","volume":"13","author":"Verhagen","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib36","first-page":"273","article-title":"Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study","volume":"22","author":"Merello","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.cger.2009.12.003_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mds.10107","article-title":"Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat","volume":"17","author":"Nash","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"165","author":"Nash","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/exnr.1998.6963","article-title":"Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat","volume":"155","author":"Nash","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/exnr.2000.7374","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors","volume":"163","author":"Steece-Collier","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1440-1681.2008.05046.x","article-title":"Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat\u00a0model of Parkinson's disease","volume":"35","author":"Leaver","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cger.2009.12.003_bib42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.410350605","article-title":"Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease","volume":"35","author":"Greenamyre","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1212\/WNL.56.4.455","article-title":"A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease","volume":"56","author":"Shoulson","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 5","key":"10.1016\/j.cger.2009.12.003_bib44","first-page":"39","article-title":"A 2-year multicenter placebo-controlled, double blind parallel group study of the effect of riluzole in Parkinson's disease [abstract]","volume":"17","author":"Rascol","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","article-title":"Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD","volume":"196","author":"Bibbiani","year":"2005","journal-title":"Exp Neurol"},{"issue":"Suppl 3","key":"10.1016\/j.cger.2009.12.003_bib46","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/S1353-8020(08)70025-7","article-title":"Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease","volume":"13","author":"Koutsilieri","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nbd.2003.09.016","article-title":"Biochemical and molecular studies of NMDA receptor subunits NR1\/2A\/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology","volume":"15","author":"Mishizen-Eberz","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib48","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1471-4159.2004.02548.x","article-title":"Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease","volume":"90","author":"Hynd","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.cger.2009.12.003_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0896-6273(04)00182-5","article-title":"Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration","volume":"42","author":"Saura","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.cger.2009.12.003_bib50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00002018-200831070-00003","article-title":"Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials","volume":"31","author":"Farlow","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.cger.2009.12.003_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2008-13110","article-title":"Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study","volume":"13","author":"Bakchine","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.STR.26.3.503","article-title":"Clinical experience with excitatory amino acid antagonist drugs","volume":"26","author":"Muir","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.cger.2009.12.003_bib53","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1523\/JNEUROSCI.1067-09.2009","article-title":"Neuroprotection by the NR3A subunit of the NMDA receptor","volume":"29","author":"Nakanishi","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib54","first-page":"255","article-title":"Intravenous magnesium sulphate in acute stroke: a randomised, double-blind, placebo-controlled pilot study [abstract]","volume":"4","author":"Muir","year":"1994","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib55","first-page":"143","article-title":"Infusion of magnesium in patients with acute brain infarction [abstract]","volume":"70","author":"Wester","year":"1984","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 2","key":"10.1016\/j.cger.2009.12.003_bib56","first-page":"A270","article-title":"Randomised trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment","volume":"44","author":"Clark","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib57","series-title":"New trends in epilepsy management: the role of gabapentin","first-page":"13","article-title":"Mechanism of action of new anti-epileptic drugs","author":"Taylor","year":"1994"},{"key":"10.1016\/j.cger.2009.12.003_bib58","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1602\/neurorx.1.1.128","article-title":"The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration","volume":"1","author":"Leegwater-Kim","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.cger.2009.12.003_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","article-title":"The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease","volume":"68","author":"Beister","year":"2004","journal-title":"J Neural Transm Suppl"},{"issue":"pt 11","key":"10.1016\/j.cger.2009.12.003_bib60","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.cger.2009.12.003_bib61","doi-asserted-by":"crossref","DOI":"10.1007\/s11481-009-9176-0","article-title":"Neuroinflammation in Parkinson's Disease","author":"Lee","year":"2009","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.cger.2009.12.003_bib62","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.neurobiolaging.2007.04.006","article-title":"Synuclein activates microglia in a model of Parkinson's disease","volume":"29","author":"Su","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.cger.2009.12.003_bib63","first-page":"182","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cger.2009.12.003_bib64","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease","volume":"98","author":"Du","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cger.2009.12.003_bib65","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease","volume":"60","author":"Chen","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U","article-title":"Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease","volume":"39","author":"Teismann","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.cger.2009.12.003_bib67","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","article-title":"Systemic inflammation and disease progression in Alzheimer disease","volume":"73","author":"Holmes","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1567205054367883","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease","volume":"2","author":"Klegeris","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.cger.2009.12.003_bib69","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0896-6273(00)80953-8","article-title":"A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion","volume":"19","author":"Li","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.cger.2009.12.003_bib70","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/exnr.1997.6429","article-title":"Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease","volume":"144","author":"Tocco","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02815208","article-title":"Inflammation and Alzheimer disease","volume":"28","author":"Aisen","year":"1996","journal-title":"Mol Chem Neuropathol"},{"key":"10.1016\/j.cger.2009.12.003_bib72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-079X.2009.00692.x","article-title":"Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease","volume":"47","author":"Olcese","year":"2009","journal-title":"J Pineal Res"},{"key":"10.1016\/j.cger.2009.12.003_bib73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0197-0186(01)00052-3","article-title":"Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha","volume":"39","author":"Combs","year":"2001","journal-title":"Neurochem Int"},{"key":"10.1016\/j.cger.2009.12.003_bib74","article-title":"Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation","author":"Denes","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.cger.2009.12.003_bib75","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/01.STR.24.11.1746","article-title":"Interleukin-1 beta mRNA expression in ischemic rat cortex","volume":"24","author":"Liu","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.cger.2009.12.003_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/01616412.1999.11740933","article-title":"Time course of IL-6 expression in experimental CNS ischemia","volume":"21","author":"Clark","year":"1999","journal-title":"Neurol Res"},{"key":"10.1016\/j.cger.2009.12.003_bib77","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.jcbfm.9600217","article-title":"Experimental stroke induces massive, rapid activation of the peripheral immune system","volume":"26","author":"Offner","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.cger.2009.12.003_bib78","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/WNL.57.8.1428","article-title":"Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab acute stroke trial","volume":"57","author":"Enlimomab Acute Stroke Trial Investigators","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib79","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.11.009","article-title":"Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke","volume":"18","author":"Banwell","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib80","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.jcbfm.9600064","article-title":"Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke","volume":"25","author":"Macleod","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.cger.2009.12.003_bib81","doi-asserted-by":"crossref","first-page":"13496","DOI":"10.1073\/pnas.96.23.13496","article-title":"A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window","volume":"96","author":"Yrjanheikki","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cger.2009.12.003_bib82","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia","volume":"95","author":"Yrjanheikki","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cger.2009.12.003_bib83","first-page":"1997","article-title":"Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage","volume":"94","author":"Hara","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cger.2009.12.003_bib84","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1523\/JNEUROSCI.21-15-05528.2001","article-title":"Role of IL-1alpha and IL-1beta in ischemic brain damage","volume":"21","author":"Boutin","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib85","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00004647-200203000-00008","article-title":"Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model","volume":"22","author":"Hughes","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.cger.2009.12.003_bib86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-5728(02)00033-4","article-title":"Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury","volume":"125","author":"Soriano","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cger.2009.12.003_bib87","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington's disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.cger.2009.12.003_bib88","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2004.09.017","article-title":"Minocycline in phenotypic models of Huntington's disease","volume":"18","author":"Bantubungi","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib89","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1073\/pnas.0737556100","article-title":"Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants","volume":"100","author":"Greene","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cger.2009.12.003_bib90","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1074\/jbc.M401135200","article-title":"Mitochondrial dysfunction and oxidative damage in parkin-deficient mice","volume":"279","author":"Palacino","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cger.2009.12.003_bib91","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson's disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cger.2009.12.003_bib92","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbrc.2005.09.178","article-title":"Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y","volume":"337","author":"Deng","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cger.2009.12.003_bib93","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000238518.34389.12","article-title":"Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial","volume":"67","author":"Bender","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib94","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","article-title":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease","volume":"66","author":"NINDS NET-PD Investigators","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2202-10-109","article-title":"Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease","volume":"10","author":"Faust","year":"2009","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/biof.5520090223","article-title":"A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease","volume":"9","author":"Shults","year":"1999","journal-title":"Biofactors"},{"key":"10.1016\/j.cger.2009.12.003_bib97","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/S1092852900020538","article-title":"Coenzyme Q10: a review of its promise as a neuroprotectant","volume":"12","author":"Young","year":"2007","journal-title":"CNS Spectr"},{"key":"10.1016\/j.cger.2009.12.003_bib98","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1427.027","article-title":"Mitochondrial approaches for neuroprotection","volume":"1147","author":"Chaturvedi","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.cger.2009.12.003_bib99","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1089\/ars.2009.2445","article-title":"Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity","volume":"11","author":"Yang","year":"2009","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.cger.2009.12.003_bib100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbadis.2009.09.013","article-title":"Abnormal mitochondrial dynamics and neurodegenerative diseases","volume":"1802","author":"Su","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cger.2009.12.003_bib101","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cbpa.2009.04.619","article-title":"Alzheimer's disease: new approaches to drug discovery","volume":"13","author":"Bolognesi","year":"2009","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.cger.2009.12.003_bib102","article-title":"Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease","author":"Kipiani","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib103","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1046\/j.1471-4159.2000.0741968.x","article-title":"Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons","volume":"74","author":"Brewer","year":"2000","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.cger.2009.12.003_bib104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1460-9568.1999.00408.x","article-title":"Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo","volume":"11","author":"Yamada","year":"1999","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000119366","article-title":"A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease","volume":"36","author":"Weyer","year":"1997","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.cger.2009.12.003_bib106","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-7091-7508-8_30","article-title":"Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study","volume":"54","author":"Gutzmann","year":"1998","journal-title":"J Neural Transm Suppl"},{"issue":"1","key":"10.1016\/j.cger.2009.12.003_bib107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbadis.2009.09.003","article-title":"Mitochondria, oxidative metabolism and cell death in stroke","volume":"1802","author":"Sims","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cger.2009.12.003_bib108","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cger.2009.12.003_bib109","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib111","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington's disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib112","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/biof.5520250113","article-title":"Clinical trials of coenzyme Q10 in neurological disorders","volume":"25","author":"Shults","year":"2005","journal-title":"Biofactors"},{"key":"10.1016\/j.cger.2009.12.003_bib113","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2006.10.023","article-title":"PGC-1alpha, a new therapeutic target in Huntington's disease?","volume":"127","author":"McGill","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cger.2009.12.003_bib114","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cger.2009.12.003_bib115","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","article-title":"SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis","volume":"26","author":"Kim","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.cger.2009.12.003_bib116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/exnr.2000.7489","article-title":"Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease","volume":"166","author":"Tatton","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib117","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1523\/JNEUROSCI.21-07-02247.2001","article-title":"Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis","volume":"21","author":"Hartmann","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib118","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00702-004-0123-1","article-title":"Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment","volume":"111","author":"Blandini","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.cger.2009.12.003_bib119","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/01.wnl.0000277648.63931.c0","article-title":"Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease","volume":"69","author":"The Parkinson Study Group PRECEPT Investigators","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib120","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1046\/j.1460-9568.2000.00181.x","article-title":"Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra","volume":"12","author":"Andringa","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib121","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(06)70602-0","article-title":"TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib122","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nbd.2004.07.021","article-title":"A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo","volume":"17","author":"Yang","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cger.2009.12.003_bib123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/4785","article-title":"Caspase inhibition reduces apoptosis and increases survival of nigral transplants","volume":"5","author":"Schierle","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.cger.2009.12.003_bib124","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1212\/WNL.66.10_suppl_4.S69","article-title":"Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease","volume":"66","author":"Olanow","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib125","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1212\/WNL.67.7_suppl_2.S30","article-title":"New pharmacologic horizons in the treatment of Parkinson disease","volume":"67","author":"Bonuccelli","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib126","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuint.2003.08.005","article-title":"N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor","volume":"44","author":"Maruyama","year":"2004","journal-title":"Neurochem Int"},{"key":"10.1016\/j.cger.2009.12.003_bib127","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/138161207780414241","article-title":"Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications","volume":"13","author":"de la Lastra","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cger.2009.12.003_bib128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(02)00263-2","article-title":"Pycnogenol protects neurons from amyloid-beta peptide-induced apoptosis","volume":"104","author":"Peng","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.cger.2009.12.003_bib129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00019052-200008000-00013","article-title":"Recent advances in Huntington's disease","volume":"13","author":"Gutekunst","year":"2000","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00401-004-0957-5","article-title":"Expression pattern of apoptosis-related markers in Huntington's disease","volume":"109","author":"Vis","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.cger.2009.12.003_bib131","article-title":"Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration?","author":"Correia","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.cger.2009.12.003_bib132","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1096\/fj.08-122275","article-title":"Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration","volume":"23","author":"Diaz-Hernandez","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.cger.2009.12.003_bib133","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jnen\/62.4.329","article-title":"Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra","volume":"62","author":"Ferrer","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib134","article-title":"Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia","author":"Yang","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.cger.2009.12.003_bib135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neuroscience.2008.08.015","article-title":"Netrin-1 attenuates ischemic stroke-induced apoptosis","volume":"156","author":"Wu","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.cger.2009.12.003_bib136","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.expneurol.2008.09.015","article-title":"Estrogen inhibits fas-mediated apoptosis in experimental stroke","volume":"215","author":"Jia","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib137","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"issue":"50","key":"10.1016\/j.cger.2009.12.003_bib138","doi-asserted-by":"crossref","first-page":"17510","DOI":"10.1073\/pnas.0405313101","article-title":"Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an \u03b1-synuclein rat model of Parkinson's disease","volume":"101","author":"Lo Bianco","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.cger.2009.12.003_bib139","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","article-title":"Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies","volume":"27","author":"Kramer","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.cger.2009.12.003_bib140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/1389450043345290","article-title":"Beta-sheet breakers for Alzheimer's disease therapy","volume":"5","author":"Bieler","year":"2004","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.cger.2009.12.003_bib141","doi-asserted-by":"crossref","first-page":"25109","DOI":"10.1074\/jbc.M003554200","article-title":"Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation","volume":"275","author":"Hughes","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cger.2009.12.003_bib142","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neulet.2003.12.077","article-title":"Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue","volume":"359","author":"Bodles","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cger.2009.12.003_bib143","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1042\/BST20051106","article-title":"Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy","volume":"33","author":"Paleologou","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.cger.2009.12.003_bib144","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1096\/fj.03-1346fje","article-title":"A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders","volume":"18","author":"El-Agnaf","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.cger.2009.12.003_bib145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0161-813X(02)00029-3","article-title":"Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein","volume":"23","author":"Masliah","year":"2002","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.cger.2009.12.003_bib146","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/bi001315u","article-title":"Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein","volume":"39","author":"Rochet","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.cger.2009.12.003_bib147","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00401-006-0096-2","article-title":"Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra","volume":"112","author":"Galvin","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.cger.2009.12.003_bib148","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1042\/BST0370692","article-title":"Inhibitors of protein aggregation and toxicity","volume":"37","author":"Amijee","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.cger.2009.12.003_bib149","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd2959","article-title":"Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies","volume":"8","author":"Brunden","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cger.2009.12.003_bib150","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/138161208786404164","article-title":"Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis","volume":"14","author":"Nagai","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cger.2009.12.003_bib151","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.cger.2009.12.003_bib152","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nurt.2008.02.003","article-title":"Treatment of Parkinson's disease with trophic factors","volume":"5","author":"Peterson","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cger.2009.12.003_bib153","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/exnr.2000.7409","article-title":"Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF","volume":"164","author":"Bensadoun","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cger.2009.12.003_bib154","first-page":"107","article-title":"GPI-1485 (Guilford)","volume":"5","author":"Marshall","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.cger.2009.12.003_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2004.06.016","article-title":"Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?","volume":"128","author":"Poulter","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.cger.2009.12.003_bib156","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1212\/WNL.66.10_suppl_4.S89","article-title":"Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease","volume":"66","author":"Dass","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2009.12.003_bib157","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/mds.21528","article-title":"Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient","volume":"22","author":"Kompoliti","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2009.12.003_bib158","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.cger.2009.12.003_bib159","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1752","article-title":"Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years","volume":"14","author":"Mendez","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.cger.2009.12.003_bib160","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm0508-483","article-title":"Assessing fetal nerve cell grafts in Parkinson's disease","volume":"14","author":"Braak","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.cger.2009.12.003_bib161","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1073\/pnas.0901402106","article-title":"Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease","volume":"106","author":"Blurton-Jones","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cger.2009.12.003_bib162","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0029-1216281","article-title":"Estrogens, episodic memory, and Alzheimer's disease: a critical update","volume":"27","author":"Henderson","year":"2009","journal-title":"Semin Reprod Med"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069009000974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069009000974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:45:47Z","timestamp":1739904347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069009000974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0749069009000974"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2009.12.003","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}